Cinepazide

Summary

Cinepazide (CHEMBL1874750) is an approved small molecule (ATC C04AX27); indicated across 2 conditions including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C04AX27
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 417.5 Da · C22H31N3O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1874750
Name	Cinepazide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5282459
ATC	C04AX27
Molecular formula	C22H31N3O5
Molecular weight	417.5
InChIKey	RCUDFXMNPQNBDU-VOTSOKGWSA-N

SMILES: COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)N2CCN(CC2)CC(=O)N3CCCC3

IUPAC name: (E)-1-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one

Also known as: Cinepazida, Cinepazide, MD 67350 FREE BASE, MD-67350 FREE BASE, SID50125834, CINEPAZIDE, CINEPAZIDE MALEATE, Cinepazide maleate

Parent form; salt/anhydrous children: CHEMBL4303265

Patent coverage: 299 distinct patent families (873 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01851759	PHASE2	UNKNOWN	Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction
NCT04951232	Not specified	COMPLETED	Clinical Study of Cinepazide Maleate Injection in the Treatment of Acute Ischemic Stroke

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).